Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential.
Meric A AltinözS GuloksuzI ElmaciPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2017)
To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.
Keyphrases
- mycobacterium tuberculosis
- public health
- end stage renal disease
- systematic review
- early stage
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- primary care
- papillary thyroid
- platelet rich plasma
- randomized controlled trial
- prognostic factors
- study protocol
- squamous cell carcinoma
- childhood cancer
- clinical trial
- disease activity
- disease virus
- machine learning
- patient reported outcomes
- free survival
- climate change
- artificial intelligence
- deep learning
- basal cell carcinoma